Deutsche Bank AG Acquires 14,540 Shares of Glaukos Co. (NYSE:GKOS)

Deutsche Bank AG lifted its position in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 49.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 43,859 shares of the medical instruments supplier's stock after purchasing an additional 14,540 shares during the period. Deutsche Bank AG owned 0.08% of Glaukos worth $6,576,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in GKOS. Rhumbline Advisers increased its position in shares of Glaukos by 0.3% during the 4th quarter. Rhumbline Advisers now owns 141,790 shares of the medical instruments supplier's stock valued at $21,260,000 after purchasing an additional 403 shares during the last quarter. IFP Advisors Inc bought a new position in Glaukos during the fourth quarter valued at about $43,000. US Bancorp DE increased its holdings in Glaukos by 8.3% during the fourth quarter. US Bancorp DE now owns 6,099 shares of the medical instruments supplier's stock worth $914,000 after buying an additional 470 shares during the last quarter. CIBC Asset Management Inc purchased a new stake in Glaukos during the fourth quarter worth about $227,000. Finally, Raymond James Financial Inc. bought a new stake in Glaukos in the fourth quarter worth about $16,910,000. 99.04% of the stock is owned by institutional investors.

Insider Transactions at Glaukos

In related news, CFO Alex R. Thurman sold 1,520 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the sale, the chief financial officer now owns 53,431 shares in the company, valued at $5,708,568.04. The trade was a 2.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 5.80% of the stock is currently owned by insiders.

Glaukos Price Performance

Shares of NYSE:GKOS traded down $2.51 on Wednesday, hitting $94.98. The company's stock had a trading volume of 1,079,542 shares, compared to its average volume of 691,403. The company has a market capitalization of $5.43 billion, a PE ratio of -33.09 and a beta of 0.83. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The company has a 50-day simple moving average of $93.78 and a 200 day simple moving average of $125.41. Glaukos Co. has a 1 year low of $77.10 and a 1 year high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last announced its earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business had revenue of $106.66 million for the quarter, compared to the consensus estimate of $102.78 million. During the same period last year, the firm posted ($0.70) earnings per share. Glaukos's quarterly revenue was up 24.6% on a year-over-year basis. Sell-side analysts forecast that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Stifel Nicolaus decreased their price target on shares of Glaukos from $140.00 to $115.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Morgan Stanley decreased their target price on Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Wells Fargo & Company lowered Glaukos from an "overweight" rating to an "equal weight" rating and lowered their target price for the company from $160.00 to $86.00 in a research note on Thursday, May 1st. Stephens decreased their price objective on Glaukos from $140.00 to $115.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Finally, Needham & Company LLC lowered their price objective on Glaukos from $176.00 to $115.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $134.67.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.